Adaptimmune Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Mar '26 Mar 5, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Market Capitalization	3	133	163	224	515	682	Upgrade
Market Cap Growth	-97.58%	-18.29%	-27.20%	-56.55%	-24.48%	506.47%	Upgrade
Enterprise Value	23	25	40	58	327	374	Upgrade
PS Ratio	0.06	0.77	2.99	8.81	95.26	210.78	Upgrade
PB Ratio	-0.06	11.63	4.56	2.92	2.84	2.44	Upgrade
P/TBV Ratio	-	17.30	4.60	2.94	2.86	2.46	Upgrade
P/FCF Ratio	-	-	-	-	271.82	-	Upgrade
P/OCF Ratio	-	-	-	-	54.60	-	Upgrade
EV/Sales Ratio	0.41	0.15	0.73	2.28	60.44	115.73	Upgrade
EV/FCF Ratio	-0.14	-	-	-	172.44	-	Upgrade
Debt / Equity Ratio	-0.69	6.26	0.64	0.28	0.12	0.07	Upgrade
Debt / FCF Ratio	-	-	-	-	11.82	-	Upgrade
Net Debt / Equity Ratio	-0.32	-6.53	-3.08	-2.22	-1.67	-1.01	Upgrade
Net Debt / EBITDA Ratio	-0.16	1.88	1.01	1.15	2.21	2.74	Upgrade
Net Debt / FCF Ratio	-0.12	1.05	0.84	1.06	-159.68	6.16	Upgrade
Asset Turnover	0.29	0.67	0.20	0.07	0.01	0.01	Upgrade
Inventory Turnover	20.28	34.25	97.02	126.15	78.45	51.66	Upgrade
Quick Ratio	1.07	2.60	2.66	3.76	6.45	9.96	Upgrade
Current Ratio	1.52	2.92	2.85	3.96	6.64	10.19	Upgrade
Return on Equity (ROE)	-1341.10%	-275.75%	-187.61%	-114.97%	-57.78%	-55.97%	Upgrade
Return on Assets (ROA)	-40.86%	-12.39%	-26.71%	-25.67%	-22.03%	-26.36%	Upgrade
Return on Capital Employed (ROCE)	-186.90%	-28.90%	-62.30%	-62.00%	-39.90%	-32.40%	Upgrade
Earnings Yield	-4216.77%	-51.37%	-63.22%	-69.17%	-26.99%	-15.59%	Upgrade
FCF Yield	-4761.05%	-53.75%	-80.82%	-71.60%	0.37%	-6.70%	Upgrade
Buyback Yield / Dilution	-8.53%	-25.48%	-24.73%	-3.47%	-9.37%	-35.72%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.